| pre-miRNA Information | |
|---|---|
| pre-miRNA | hsa-mir-3689a |
| Genomic Coordinates | chr9: 134849487 - 134849564 |
| Description | Homo sapiens miR-3689a stem-loop |
| Comment | None |
| RNA Secondary Structure |  |
| Mature miRNA Information | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mature miRNA | hsa-miR-3689a-5p | |||||||||||||||||||||
| Sequence | 10| UGUGAUAUCAUGGUUCCUGGGA |31 | |||||||||||||||||||||
| Evidence | Experimental | |||||||||||||||||||||
| Experiments | Illumina | |||||||||||||||||||||
| SNPs in miRNA |
|
|||||||||||||||||||||
| Putative Targets | ||||||||||||||||||||||
| miRNA Expression profile | |
|---|---|
| Human miRNA Tissue Atlas | |
| Circulating MicroRNA Expression Profiling | |
| Gene Information | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Symbol | ZBTB39 | ||||||||||||||||||||
| Synonyms | ZNF922 | ||||||||||||||||||||
| Description | zinc finger and BTB domain containing 39 | ||||||||||||||||||||
| Transcript | NM_014830 | ||||||||||||||||||||
| Expression | |||||||||||||||||||||
| Putative miRNA Targets on ZBTB39 | |||||||||||||||||||||
| 3'UTR of ZBTB39 (miRNA target sites are highlighted) |
>ZBTB39|NM_014830|3'UTR 1 CTGGGTCCCGGCAGAGCCACGGGGAGCTCCCAAGCAGCAGCCAGGATGCTGATATCTAAGAGGTGTTGGTCCCTCCCCAG 81 CTGAAGTTATAATTTTGCCTTGGTAGGAATTCTGTTCTGTGTTGTGTTTAAAGAAGAAAAGAAGAAGAAATAGCACATAA 161 GCTGTTACTGTTGTTGAGAAGCAACAGCCCTATCACATTTACCTCCATACCTGTTCTTGCCCATGCAGGGCTATGTTTTT 241 CATTCTTTTGAGGCTGGTTTTGGGATCTAGTCAAGCAGTTGGTGTCCACTAGACCCCCTTCCCCAGCCTCTCTAGTTTTA 321 GTTTACTGATAGGTTTTATGCTGCTAAGAATCCAACCAACAGCCTCACTTAACAGAGGAGGTAAAGGGAGGTTTTCACTG 401 TGGGTGTTACTGCAGGCCTCCAACTGGGATGACCAGCAATGAGAAAGATTTTGGGAATGTGATCATTCAGAAAAGACAGG 481 TCAGCAGGGCAGTCCCCTCAGGTTCCAGCCCTCAGCAGGGACAAGACATCAGGGATGTTGGTGTCTGCTTATCTACAGCC 561 CTAATCTGCTGATTGAACAGTGAAAATCTTTTGGCAGCTAGATCCATACTAGGCACAGAGCTTTCTATTTAGGTCAGAAA 641 GCTTTGGGATGAACCCCTGCCAGCCAGAAGGGGTGTCCTGCAGTGCCACCAGAAGTGGCAGCCTGGATGGACAGGAGAGG 721 TTTCTCTTTTCTCCTCATTTCCAAAGAAACAGGATTTTATGGAGTGATGGCCCGGGACGTCCGGCCTTCTGTGGGGCAGA 801 GAGGATAGGGAACCACTTTGATATAGTCATCTGTTTTGGCCACTTCTGTTGGCCATGAGTGTCTTGGTGGAGAGGTGGGG 881 ATGTATCTGACAGCAGCAGCCTTGCCTTAATTTATATCTGGTCTCCCGTCCAGAAGTGTTTGGCCCGTGGTGTAGATGAG 961 CTGACTCCATGAAGTGGTGGAGTGGCAGACCGCGAGCCCTTCAGGATTAAAGGGACCTGAGTAACTGGTGGTGTGTAGCA 1041 GGGTGTGCGTTCTGACTGTCTGTCCTAGTCGGGTAACCTGTTTACTTTGTGCTAACAGTGCCGGAGCTTTGTCAGCTCAC 1121 CTTTGACCTGCTGGAATTTATCCTGATCTGTCGTTGCCATCACCTCCAGGGGGCGCTATTGGATGGCAGCTGGTTCAGGC 1201 CCTCCGTGGGTGGCTGCAGAGTGTGCCGGCACAGCCCACGCAGCTGGTTAGCTCCACTCTTACTTGGTTTTCTAAGGGGC 1281 TTTGCCCAAAGAAGTCTTGAGGGATAGGGCCCTCGATCTTGCATACTTGTGAGGTGCCACCTCAGTAGCTCATACTACCT 1361 CACCCTGCTCAGGTGAGCTCTGGGAGTCCCTGGCCTCAGCCCTGGCACTGCCCCTGGTGGGATTCAGCAACACCCCGGGC 1441 TGTTTCACAAGCAAGTGGTTTTCATTAACTCACAAAGCCTTTTTGGACATTAATATTTATTTATTTTTGTTTTTGTATAC 1521 ACATTACCCAGCATCTCTTTTGTATAAGAGACTTTAGGAAAATGAGTTTCTCCCCAGCAAGTAGCCATATTCCAGAGAAC 1601 AGCCTTGACCAGAGATGTGGAGAACCAGGGGTATAACTAAGGGAAGACATGTCAAGCCCTTAAGCAAATTCTTCTTCTCC 1681 AGATTGTCTCTAGCATAATAAACCCAGGGAACACTTTAGGCCATGGGTGTATGTTCTATAAAGTTCGGGACAGTTAAATT 1761 CCAGGCCTTTCATCCCCCTTCCTTCCTGTGATGGAGTAGATTGGGGACAGGGTTGAGGGGAACAAGTGACATGAATGACC 1841 TATTTGCACAGTTTGGAAGCCTCCTGTCTTTATTTATATTGAGATGTCAGACAAACCAAAGCTCCATCCTTGTTGGACCT 1921 GCTGCTTCTCCCCAGCCCTGAACTGATAAAGCCTCAGAGTTGGAGTGCCTGGCTCTCTGGTGGGGTGACCATTAGATGAA 2001 GGGACTTGTACAGTGGCCAGTTTAAAGGTCCACCTTTGACCATCTAAACCCACCTTGTTCAGTGTCCTCTGAGGACATCC 2081 TCATCAGGAAAGCAGTGTTGAGACTCTTCATTGCTGACTGGCTTCTCCCTTTCTTACTCACACTGACCATTAGAATTTAA 2161 GAAGGAAATGTGTAACAGACTACAGTCAAGTGTCTGCTACATTTTCAAGCATGAGCAATCCCTCCCAGACTGTTGGTGAG 2241 GACTGATTTTTGAAATGCTGGTGTGAGAGAGGTGGTAATTACAGGAACCAGCCGAGTGGCTGAGAGCAGATAAATGTGCT 2321 GGAGAAACCTTTTTCCTTAACAGAGGGCATCATGGATGCTGGGTGGTCTGTGTACTTAACCTGAAACTGTGAAGTTTTCC 2401 CTTTTTGCCAGTAAACCAAAAAGCAGATCCTTGAAACTTGGCCCTTGAAACACGAAACAGAAAACTGCATCCCCTGATCC 2481 CCCGGGGGCTGATCAGATTGATCAGGGTGGCTCAGTTGGTCCCAGTCAGATACGTCATAGGATCAGTAGCTCATGAGATT 2561 TGTTGACCAAACCCTCTCCCTGTTGGTGACCCCTGTATTCACACCTGAACTTCCCGTTTCCCCCCACCCCACCAAAGTCA 2641 TGTCTGCTTCCTCTGCCTCCAGCTCACCCTCTTCTGAATGGTTTTGCTTGAAACACTATATTGTGGCAGAGGGCACCCTG 2721 GGATACCTGGTAGAAGGTATTCATTTTATTTTGCATTTTTAATTGTTTTGACTTTCTGTTCATTTGATTTTGTTGCTCCC 2801 TCTCTCCTGGAACCTAGTTTACTACTCTCTTCTGTGTTACTCTGAAGTTCTGTTTAAGCCTTGAACATCCTCTTCTCCCA 2881 TTTTCTTGGTATGTACTCAGGACCAGCTACATCATTTGTGGAGCCCTCTTATTCATAAATTATTAAAAATTTCAAGGTGG 2961 TGGTCATAGAGCATTAAACCAAATATGAGGCCATTCCCAACTTGTTTTCCGAGGGGAAAATGGTAATACTTGTGTGGCAC 3041 CCGGGGTTAAACAGCAGAGGCTCCATGTGGCCAGAGGCAGAGATTAGTATCCTGGCACTCCAGTGACCCACTGGGTGACT 3121 CACTGATGCCACAGCACCCGCTAGGAAGCTCTGCTGAACCTTAGTATTTGGTCCTAAATTTTATGACTCCATGGAGTTCC 3201 CGTAGTCCATGGCTAGTTAGGAAGAAAGGAGGTGGGATAAGGGTCAGGCCCAGGTGACCCCTAAGAACCAGGAGATGGGT 3281 AAAAGTTTTTTTTTATATTCTGCTTTTCTGATCTGTGAGTACCTGTTTGTCTCCAGGCCAAACCTTTGGGCTTAAATATC 3361 TTTTTCCTAGACAGGTTTTTGCTAGTGTTGAATTTTCTTCTTCCTCTGGCCTCCTTCTGTGCCCCTTTCCCCAAGCCCAA 3441 GACTGCTTAACTTCCAAAGCAAATTCTAGATAGACACTGTATTTATTGGTATGGGAGTGGGCTCTATGGGGTGGTCTGCA 3521 CCCATCTGGGACTCTTTTCCCTAAATCCTGCACCAAATGAGTCAGGAGGCAGGGTGCACAGCATTAGTTTCAATGTGGTT 3601 ATGCATCATAAGCTTAACATCAGAATGAAAATGAAACTCGATTTTGATGTTTCTTTAAAACCCTTCCCCTGTCCAATCCA 3681 CTCGCCGCCCCCACCTTGAATAGCTAAAGTCTCTTATGAAACAGAGAAGAGTTGTTGACGTCTAACTCCTTCCATTAAAT 3761 TAATAAGTACTGACCTCCTAATATTTAAGTGTTTACTATCTATTGCTGTAAAGTTTTGTATATTTTGTAAACTTTTTTCC 3841 CCAAATAGTAGATGTCTAAAATCATTGTACATCTGATTCTTTTATATTCCATTGTTCAGCACAAAGTGTGGTTTTTATTT 3921 AGAATAAAAAAAGAAATTTGAAATGAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
| miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
| DRVs in gene 3'UTRs | |||||||||||||||||||||
| SNPs in gene 3'UTRs | |||||||||||||||||||||
| Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
|---|---|---|---|---|---|---|---|
| miRNA:Target | ---- | ||||||
| Validation Method |
|
||||||
| Conditions | HEK293 | ||||||
| Location of target site | 3'UTR | ||||||
| Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
| Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
| miRNA-target interactions (Provided by authors) |
|
||||||
| Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
||||||
| Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
|---|---|---|---|---|---|---|---|
| miRNA:Target | ---- | ||||||
| Validation Method |
|
||||||
| Conditions | HEK293 | ||||||
| Disease | 9880.0 | ||||||
| Location of target site | 3'UTR | ||||||
| Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
| Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1065670. RNA binding protein: AGO2. Condition:4-thiouridine
... - Memczak S; Jens M; Elefsinioti A; Torti F; et al., 2013, Nature. |
||||||
| miRNA-target interactions (Provided by authors) |
|
||||||
| Article |
- Memczak S; Jens M; Elefsinioti A; Torti F; et al. - Nature, 2013
Circular RNAs (circRNAs) in animals are an enigmatic class of RNA with unknown function. To explore circRNAs systematically, we sequenced and computationally analysed human, mouse and nematode RNA. We detected thousands of well-expressed, stable circRNAs, often showing tissue/developmental-stage-specific expression. Sequence analysis indicated important regulatory functions for circRNAs. We found that a human circRNA, antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is densely bound by microRNA (miRNA) effector complexes and harbours 63 conserved binding sites for the ancient miRNA miR-7. Further analyses indicated that CDR1as functions to bind miR-7 in neuronal tissues. Human CDR1as expression in zebrafish impaired midbrain development, similar to knocking down miR-7, suggesting that CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. Together, our data provide evidence that circRNAs form a large class of post-transcriptional regulators. Numerous circRNAs form by head-to-tail splicing of exons, suggesting previously unrecognized regulatory potential of coding sequences.
LinkOut: [PMID: 23446348]
|
||||||
| Experimental Support 3 for Functional miRNA-Target Interaction | |
|---|---|
| miRNA:Target | ---- |
| Validation Method |
|
| Conditions | TZM-bl |
| Location of target site | 3'UTR |
| Tools used in this research | TargetScan , miRTarCLIP , Piranha |
| Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
| Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
| Experimental Support 4 for Functional miRNA-Target Interaction | |
|---|---|
| miRNA:Target | ---- |
| Validation Method |
|
| Conditions | Prostate Tissue |
| Location of target site | 3'UTR |
| Tools used in this research | TargetScan , miRTarCLIP , Piranha |
| Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760630. RNA binding protein: AGO2. Condition:AGO-CLIP-22RV1_A
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
| Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
| CLIP-seq Support 1 for dataset GSM545216 | |
|---|---|
| Method / RBP | PAR-CLIP / AGO2 |
| Cell line / Condition | HEK293 / miR-124 transfection |
| Location of target site | ENST00000300101.2 | 3UTR | CCCUAUCACAUUUACCUCCAUACCU |
| Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
| Article / Accession Series | PMID: 20371350 / GSE21578 |
| CLIP-seq Viewer | Link |
| CLIP-seq Support 2 for dataset GSM1065670 | |
|---|---|
| Method / RBP | PAR-CLIP / AGO2 |
| Cell line / Condition | HEK293 / 4-thiouridine, 3_ML_LG |
| Location of target site | ENST00000300101.2 | 3UTR | CCCUAUCACAUUUACCUCCAU |
| Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
| Article / Accession Series | PMID: 23446348 / GSE43573 |
| CLIP-seq Viewer | Link |
| CLIP-seq Support 3 for dataset GSM1462574 | |
|---|---|
| Method / RBP | PAR-CLIP / AGO2 |
| Cell line / Condition | TZM-bl / TZM-bl ami BaL |
| Location of target site | ENST00000300101.2 | 3UTR | CAACAGCCCUAUCACAUUUACCUCCAUACCUG |
| Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
| Article / Accession Series | PMID: 23592263 / GSE59944 |
| CLIP-seq Viewer | Link |
| MiRNA-Target Expression Profile | |||||||
|---|---|---|---|---|---|---|---|
|
| MiRNA-Target Expression Profile (TCGA) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
45 hsa-miR-3689a-5p Target Genes:
Functional analysis:
ID |
Target | Description | Validation methods |
 |
 |
|||||||
| Strong evidence | Less strong evidence | |||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|||||
| MIRT112230 | MDM4 | MDM4, p53 regulator |  |
|
2 | 2 | ||||||
| MIRT188656 | FAM76A | family with sequence similarity 76 member A | |
|
2 | 2 | ||||||
| MIRT200911 | ZNF264 | zinc finger protein 264 | |
|
2 | 4 | ||||||
| MIRT210595 | KBTBD8 | kelch repeat and BTB domain containing 8 | |
|
2 | 6 | ||||||
| MIRT299207 | CSRNP3 | cysteine and serine rich nuclear protein 3 | |
|
2 | 2 | ||||||
| MIRT317524 | SLC39A7 | solute carrier family 39 member 7 | |
|
2 | 2 | ||||||
| MIRT355849 | SGMS2 | sphingomyelin synthase 2 | |
|
2 | 4 | ||||||
| MIRT443052 | THRB | thyroid hormone receptor beta | |
|
2 | 2 | ||||||
| MIRT446631 | SDC3 | syndecan 3 | |
|
2 | 2 | ||||||
| MIRT449409 | TRIM5 | tripartite motif containing 5 | |
|
2 | 2 | ||||||
| MIRT463561 | ZBTB39 | zinc finger and BTB domain containing 39 | |
|
2 | 6 | ||||||
| MIRT465704 | TNFAIP1 | TNF alpha induced protein 1 | |
|
2 | 2 | ||||||
| MIRT472688 | MYCBP | MYC binding protein | |
|
2 | 4 | ||||||
| MIRT493287 | LNPEP | leucyl and cystinyl aminopeptidase | |
|
2 | 2 | ||||||
| MIRT499338 | RAB25 | RAB25, member RAS oncogene family | |
|
2 | 2 | ||||||
| MIRT501723 | OVOL1 | ovo like transcriptional repressor 1 | |
|
2 | 2 | ||||||
| MIRT507977 | BCL2L13 | BCL2 like 13 | |
|
2 | 4 | ||||||
| MIRT511811 | HDGF | heparin binding growth factor | |
|
2 | 6 | ||||||
| MIRT516711 | PIK3CG | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | |
|
2 | 4 | ||||||
| MIRT527853 | SMOC1 | SPARC related modular calcium binding 1 | |
|
2 | 2 | ||||||
| MIRT531286 | SLC7A7 | solute carrier family 7 member 7 | |
|
2 | 2 | ||||||
| MIRT531894 | INVS | inversin | |
|
2 | 8 | ||||||
| MIRT536807 | HNRNPA1 | heterogeneous nuclear ribonucleoprotein A1 | |
|
2 | 2 | ||||||
| MIRT537807 | EFNB2 | ephrin B2 | |
|
2 | 4 | ||||||
| MIRT544335 | LPGAT1 | lysophosphatidylglycerol acyltransferase 1 | |
|
2 | 2 | ||||||
| MIRT547142 | PGM3 | phosphoglucomutase 3 | |
|
2 | 2 | ||||||
| MIRT547429 | MED4 | mediator complex subunit 4 | |
|
2 | 2 | ||||||
| MIRT563354 | ZNF181 | zinc finger protein 181 | |
|
2 | 2 | ||||||
| MIRT564849 | ZBED3 | zinc finger BED-type containing 3 | |
|
2 | 2 | ||||||
| MIRT566426 | PIGA | phosphatidylinositol glycan anchor biosynthesis class A | |
|
2 | 2 | ||||||
| MIRT572512 | KIAA0232 | KIAA0232 | |
|
2 | 2 | ||||||
| MIRT574682 | HNRNPA3 | heterogeneous nuclear ribonucleoprotein A3 | |
|
2 | 2 | ||||||
| MIRT608820 | ONECUT3 | one cut homeobox 3 | |
|
2 | 6 | ||||||
| MIRT608886 | CLIC6 | chloride intracellular channel 6 | |
|
2 | 2 | ||||||
| MIRT608959 | GIMAP1 | GTPase, IMAP family member 1 | |
|
2 | 4 | ||||||
| MIRT609012 | HPS3 | HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 | |
|
2 | 2 | ||||||
| MIRT641431 | SCUBE3 | signal peptide, CUB domain and EGF like domain containing 3 | |
|
2 | 2 | ||||||
| MIRT661841 | ZNF587B | zinc finger protein 587B | |
|
2 | 2 | ||||||
| MIRT690651 | RPF2 | ribosome production factor 2 homolog | |
|
2 | 2 | ||||||
| MIRT704619 | CLIP1 | CAP-Gly domain containing linker protein 1 | |
|
2 | 2 | ||||||
| MIRT708714 | PTPLAD2 | 3-hydroxyacyl-CoA dehydratase 4 | |
1 | 1 | |||||||
| MIRT710663 | CSTF2T | cleavage stimulation factor subunit 2 tau variant | |
|
2 | 2 | ||||||
| MIRT711260 | TPCN2 | two pore segment channel 2 | |
|
2 | 2 | ||||||
| MIRT714649 | FSTL1 | follistatin like 1 | |
|
2 | 2 | ||||||
| MIRT718518 | COL19A1 | collagen type XIX alpha 1 chain | |
|
2 | 2 | ||||||
| miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|